NovoCure Limited

18.51
0.74 (4.16%)
At close: Apr 24, 2025, 3:59 PM
19.22
3.83%
After-hours: Apr 24, 2025, 07:36 PM EDT
4.16%
Bid 17.4
Market Cap 2.06B
Revenue (ttm) 605.22M
Net Income (ttm) -168.63M
EPS (ttm) -1.56
PE Ratio (ttm) -11.87
Forward PE -7.94
Analyst Buy
Ask 21.04
Volume 1,167,975
Avg. Volume (20D) 875,675
Open 18.75
Previous Close 17.77
Day's Range 17.40 - 19.25
52-Week Range 11.88 - 34.13
Beta 0.65

About NVCR

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed c...

Sector Healthcare
IPO Date Oct 1, 2015
Employees 1,488
Stock Exchange NASDAQ
Ticker Symbol NVCR
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 72.88% from the latest price.

Stock Forecasts

Earnings Surprise

NovoCure has released their quartely earnings on Apr 24, 2025:
  • Revenue of $154.99M exceeds estimates by $7.99M, with 11.91% YoY growth.
  • EPS of -0.31 exceeds estimates by 0.15, with 13.89% YoY growth.
  • Next Earnings Release

    NovoCure Limited is scheduled to release its earnings on Apr 24, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    -12.43%
    NovoCure shares are trading lower after the compan... Unlock content with Pro Subscription
    4 months ago
    +11.14%
    NovoCure shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $28 to $42.